DE60110912T2 - Valproinsäure und deren derivate als histondeacetylaseinhibitoren - Google Patents

Valproinsäure und deren derivate als histondeacetylaseinhibitoren Download PDF

Info

Publication number
DE60110912T2
DE60110912T2 DE60110912T DE60110912T DE60110912T2 DE 60110912 T2 DE60110912 T2 DE 60110912T2 DE 60110912 T DE60110912 T DE 60110912T DE 60110912 T DE60110912 T DE 60110912T DE 60110912 T2 DE60110912 T2 DE 60110912T2
Authority
DE
Germany
Prior art keywords
vpa
cells
cancer
hdac
histone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60110912T
Other languages
German (de)
English (en)
Other versions
DE60110912D1 (de
Inventor
Martin GÖTTLICHER
Thorsten Heinzel
Bernd Groner
Peter Herrlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Application granted granted Critical
Publication of DE60110912D1 publication Critical patent/DE60110912D1/de
Publication of DE60110912T2 publication Critical patent/DE60110912T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60110912T 2000-07-07 2001-07-05 Valproinsäure und deren derivate als histondeacetylaseinhibitoren Expired - Lifetime DE60110912T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00114088 2000-07-07
EP00114088A EP1170008A1 (en) 2000-07-07 2000-07-07 Valproic acid and derivatives thereof as histone deacetylase inhibitors
PCT/EP2001/007704 WO2002007722A2 (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
DE60110912D1 DE60110912D1 (de) 2005-06-23
DE60110912T2 true DE60110912T2 (de) 2005-10-20

Family

ID=8169134

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110912T Expired - Lifetime DE60110912T2 (de) 2000-07-07 2001-07-05 Valproinsäure und deren derivate als histondeacetylaseinhibitoren

Country Status (10)

Country Link
US (2) US7265154B2 (https=)
EP (2) EP1170008A1 (https=)
JP (1) JP2004504347A (https=)
AT (1) ATE295725T1 (https=)
AU (2) AU8392501A (https=)
CA (1) CA2414967C (https=)
DE (1) DE60110912T2 (https=)
ES (1) ES2239677T3 (https=)
PT (1) PT1301184E (https=)
WO (1) WO2002007722A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
AU2002313817A1 (en) * 2001-08-27 2003-03-10 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
ATE458047T1 (de) 2002-03-07 2010-03-15 Univ Delaware Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006509010A (ja) * 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド アポトーシスの制御
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
ES2308065T3 (es) * 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
KR100659779B1 (ko) 2004-09-04 2006-12-19 주식회사 바이넥스 히스톤 디아세틸라제 억제제를 함유하는 중간엽줄기세포의 골분화유도용 조성물 및 이를 이용한 골분화증가방법
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
US20120165384A1 (en) * 2009-09-07 2012-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Inhibition of histone acetyltransferases by ctk7a and methods thereof
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
CN107073014A (zh) * 2014-05-02 2017-08-18 翁科埃斯克斯有限公司 利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法
CN105622712B (zh) * 2014-10-27 2019-08-27 天津金耀集团有限公司 一种甾体3-酮-4-烯物合成工艺
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20210076048A (ko) * 2018-10-12 2021-06-23 라이프 테크놀로지스 코포레이션 조혈 줄기 및 전구 세포 확장 시스템
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
WO1997011366A1 (en) * 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997047307A1 (en) * 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
WO1998029114A1 (en) * 1996-12-30 1998-07-09 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
EP1037533A1 (en) * 1997-11-10 2000-09-27 The Salk Institute for Biological Studies Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors

Also Published As

Publication number Publication date
CA2414967C (en) 2009-08-25
PT1301184E (pt) 2005-07-29
JP2004504347A (ja) 2004-02-12
EP1170008A1 (en) 2002-01-09
AU8392501A (en) 2002-02-05
CA2414967A1 (en) 2002-01-31
AU2001283925B2 (en) 2005-07-14
ATE295725T1 (de) 2005-06-15
US20040087652A1 (en) 2004-05-06
US20070232696A1 (en) 2007-10-04
EP1301184A2 (en) 2003-04-16
DE60110912D1 (de) 2005-06-23
US7265154B2 (en) 2007-09-04
EP1301184B1 (en) 2005-05-18
WO2002007722A2 (en) 2002-01-31
ES2239677T3 (es) 2005-10-01
WO2002007722A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DE60110912T2 (de) Valproinsäure und deren derivate als histondeacetylaseinhibitoren
AU2001283925A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
Perlmann et al. Nuclear receptors in Sicily: all in the famiglia
DE60208397T2 (de) Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung
DE69829183T2 (de) Synthese und verwendung von retinoiden mit negativen hormonellen und/oder antagonistischen wirkungen
Su et al. Contribution of Na+-K+-Cl− cotransporter to high-[K+] o-induced swelling and EAA release in astrocytes
DE60031396T2 (de) Zubereitung zur behandlung einer neurologischen erkrankung
DE69326014T2 (de) Dithiocarbamate zur behandlung von atheroskerosis und weiteren kardiovasculären und entzündlichen erkrankungen
DE69720745T2 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
DE69434211T2 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
Nelson et al. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes
Huang et al. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant α1β2γ2L GABAA receptors
Nagpal et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi’s sarcoma
DE69029654T2 (de) Verwendung von lipoxin a 4? und dessen derivaten als antagonisten für trägreagierende anaphylaxmittel
US20090093546A1 (en) Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
Liu et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18
US20210113512A1 (en) Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
Lee et al. Fatty acid–binding protein 5 mediates the uptake of fatty acids, but not drugs, into human brain endothelial cells
Kochhar et al. Differential teratogenic response of mouse embryos to receptor selective analogs of retinoic acid
Di Giovanni et al. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons
Yang Ceramide-induced sustained depression of synaptic currents mediated by ionotropic glutamate receptors in the hippocampus: an essential role of postsynaptic protein phosphatases
Hong et al. A novel role of lactate: Promotion of Akt-dependent elongation of microglial process
Hong et al. A novel Glycyrrhiza glabra extract liquiritin targeting NFATc1 activity and ROS levels to counteract ovariectomy-induced osteoporosis and bone loss in murine model
Mishra et al. Attenuating Aβ1–42-induced toxicity by a novel acetylcholinesterase inhibitor
Zhang et al. Hydroxycitric acid inhibits kidney stone through crystallization regulation and reduction of hyperoxalate-induced lipotoxicity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition